Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Global Study to Investigate Combination Regimens Containing Margetuximab for the Treatment of Gastric Cancer

Trial Profile

A Global Study to Investigate Combination Regimens Containing Margetuximab for the Treatment of Gastric Cancer

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Margetuximab (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Dec 2018 New trial record
    • 29 Nov 2018 According to a MacroGenics media release, MacroGenics and Zai Lab Limited have entered into an exclusive collaboration and license agreement involving three immuno-oncology programs from MacroGenics pipeline of product candidates. As part of this agreement, both the companies intend to initiate this global study using combination regimens containing margetuximab in order to maximize potential clinical benefit in gastric cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top